Caris Life Sciences, Inc. (CAI) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Positive catalyst stack with Q1 2026 revenue of $216.2M, up 79% YoY, plus Caris MI Clarity launch, Caris ChromoSeq launch and MolDX approval, NY State authorization filing for Caris Assure, and a $100M share repurchase program announced on 2026-06-08.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Thin margins ⢠Preferred burden CAI has strong liquidity and cash generation, but thin margins, ongoing losses, and a heavy preferred-share burden make the common equity case unattractive.
Price Behavior
Key Price Behavior Insights: ⢠Mid-$15 support ⢠Higher-low pattern ⢠Rebound stalled Support Level: $15.4 to $15.6 Resistance Level: $17.3 Over the last month, CAI is still in a broader downtrend but has stabilized above mid-$15 support, and it needs a clean move back through $17.3 to confirm a stronger rebound; otherwise, caution remains.
Sentiment & News
Key News Insights: ⢠Revenue Surge ⢠Multicloud Partnerships ⢠Clinical Validation Caris Life Sciences drove CAI's headlines with strong Q1 revenue growth, expanding partnerships, and new regulatory/scientific milestones that reinforce its AI-enabled precision medicine strategy.
AI Summary
CAI now looks less like a pure AI/science story and more like an execution test: strong liquidity and revenue growth give it runway, but with only ~3% operating margin, heavy preferred-share drag, and a weak chart below the $17s, investors need proof that commercial momentum is translating into durable common-share value.
Description
Caris Life Sciences is a US-based provider of molecular profiling services and related laboratory and data offerings to clinical and biopharmaceutical customers worldwide. The company supplies tissue- and blood-based tests for cancer treatment selection and supports drug development through laboratory execution, data products, and research services. Founded in 2008, Caris is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jun 9 | Jun 16 | CAI | Caris Life Sciences, Inc. | Positive catalyst stack with Q1 2026 revenue of $216.2M, up 79% YoY, plus Caris MI Clarity launch, Caris ChromoSeq launch and MolDX approval, NY State authorization filing for Caris Assure, and a $100M share repurchase program announced on 2026-06-08. | Active | +6.0% |